ArticleBlood vessels, thrombosis & hemostasis2025
Role of azathioprine in the management of ITP in the TPO-RA era: a single-center retrospective study.
Article in Blood vessels, thrombosis & hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.Blood advances · 2026Article
- Immune thrombocytopenia: Evolving mechanistic understanding and clinical development of new therapies.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Access to modern therapeutics for immune thrombocytopenia (ITP), such as thrombopoietin-receptor agonists (TPO-RAs), remains a challenge, limiting clinicians' options. We investigated azathioprine in relapsed/refractory ITP to determine its efficacy and safety, focusing on evaluating its utility in post-TPO-RA patients. We retrospectively reviewed all adult patients, aged ≥18 years, who were worked up for thrombocytopenia between 2009 and 2022 at a tertiary care center in Ontario, Canada. Only patients with ITP treated with azathioprine were included. We identified 92 patients with ITP who received azathioprine, with a mean age of 55.6 ± 22.3 years; 53 were females and 39 males, with 64 having primary ITP. The overall response rate (ORR) was 47.8% (44/92), with a sustained response rate of 77.3% (34/44) at 6 months. The median time to response was 6 weeks. Fourteen patients (31.8%) relapsed, with a median duration of response of 10 weeks. Most patients (73.9%) had documented side effects, with nausea/vomiting, infections, and myelosuppression being the most common. The majority of patients received azathioprine as third-line therapy; 6 patients after TPO-RA and 27 after splenectomy. ORR was 50.0% (3/6) and 40.7% (11/27) in each group, respectively. This is the largest retrospective study, to our knowledge, demonstrating benefit with azathioprine in relapsed/refractory ITP. Its efficacy remains consistent both after TPO-RA (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.